
Phio Pharmaceuticals Reaches Milestone: Second Cohort Fully Enrolled in Phase 1b Dose-Escalating Clinical Study
Six Clinical Sites Across the U.S. Engaged in Phase 1b Study Phio Pharmaceuticals Corp. Completes Enrollment for PH-762 Trial Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient…